美股詳情

本頁面由Tiger Trade Technology Pte. Ltd.提供服務

Invea Therapeutics, Inc.

成交量：- -

成交額：- -

市值：- -

市盈率：- -

高：- -

開：- -

低：- -

收：- -

52周最高：- -

52周最低：- -

股本：- -

流通股本：- -

量比：- -

換手率：- -

股息：- -

股息率：- -

淨資產收益率：--

總資產收益率：--

市淨率：0.00

市盈率(LYR):- -

資料載入中...

總覽公司新聞資訊公告

公司資料

公司名字：

Invea Therapeutics, Inc.

交易所：

NASDAQ

成立時間：

- -

員工人數：

- -

公司地址：

- -

官網：

http://www.inveatx.com

郵編：

- -

電話：

- -

傳真：

- -

簡介：

Invea Therapeutics, Inc.於2021年10月20日根據特拉華州法律成立。該公司是一家生物技術公司，專註於開發用於免疫介導的炎症性疾病（IMIDs）的口服小分子療法。目前，該公司有兩個候選產品：INVA8001，旨在治療慢性誘發性蕁麻疹，以及INVA8003，他處於早期臨床前開發階段，在各種IMID中有更廣泛的應用。INVA8001計劃在歐盟推進2a期臨床開發。通過採用AlphaMeld平台，該平台集成了人工智能和機器學習等先進技術，該公司旨在識別和開發安全、有效的口服療法，不僅可以解決炎症問題，還可以提高IMID患者的生活質量。

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/stock/INAI/company"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"INAI","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"INAI\",,,,,undefined,":{"symbol":"INAI","market":"US","secType":"STK","nameCN":"Invea Therapeutics, Inc.","latestPrice":0,"timestamp":0,"preClose":0,"halted":9,"volume":0,"delay":0,"floatShares":0,"shares":0,"eps":0,"marketStatus":"交易中","change":0,"latestTime":"02-24 10:39:44 EST","open":0,"high":0,"low":0,"amount":0,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":0,"tradingStatus":2,"nextMarketStatus":{"tag":"盤後交易","tradingStatus":3,"beginTime":1771966800000},"marketStatusCode":2,"adr":0,"listingDate":1770267600000,"exchange":"NASDAQ","adjPreClose":0,"volumeRatio":0},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"INAI\",,,,,undefined,":{"symbol":"INAI","floatShares":0,"roa":"--","roe":"--","lyrEps":0,"shares":0,"dividePrice":0,"high":0,"amplitude":0,"preClose":0,"low":0,"week52Low":0,"pbRate":"0.00","week52High":0,"institutionHeld":0,"latestPrice":0,"eps":0,"divideRate":0,"volume":0,"delay":0,"ttmEps":0,"open":0},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/INAI\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"INAI\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"INAI\",market:\"US\",delay:false,,,undefined,":{},"@#url:\"stock.company.info\",,undefined,":{"stockCompanyProfile":{},"stockCompanyDetail":{"websiteUrl":"http://www.inveatx.com","compareEarnings":[{"period":"1week","weight":0.0009},{"period":"1month","weight":-0.0099},{"period":"3month","weight":0.0109},{"period":"6month","weight":0.0553},{"period":"1year","weight":0.1374},{"period":"ytd","weight":0.0007}],"compareStock":{"symbol":"SPY","name":"標普500ETF"},"description":"Invea Therapeutics, Inc.於2021年10月20日根據特拉華州法律成立。該公司是一家生物技術公司，專註於開發用於免疫介導的炎症性疾病（IMIDs）的口服小分子療法。目前，該公司有兩個候選產品：INVA8001，旨在治療慢性誘發性蕁麻疹，以及INVA8003，他處於早期臨床前開發階段，在各種IMID中有更廣泛的應用。INVA8001計劃在歐盟推進2a期臨床開發。通過採用AlphaMeld平台，該平台集成了人工智能和機器學習等先進技術，該公司旨在識別和開發安全、有效的口服療法，不僅可以解決炎症問題，還可以提高IMID患者的生活質量。","exchange":"NASDAQ","name":"Invea Therapeutics, Inc.","nameEN":"Invea Therapeutics, Inc."}},"@#url:\"https://hq.skytigris.cn/fundamental/company/manager/list\",params:#symbol:\"INAI\",market:\"US\",,,undefined,":null}}